Immuno-stimulation With Maraviroc Combined to Antiretroviral Therapy in Advanced Late Diagnosed HIV-1 Infected Patients (OPTIMAL)

ANRS, Emerging Infectious Diseases

Status and phase

Completed

Phase 3

Conditions

AIDS

HIV-1 Infection

Treatments

Drug: Maraviroc (Celsentri)

Drug: Placebo

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT01348308

2010-022293-14

ANRS 146 OPTIMAL

Details and patient eligibility

About

The objective of the OPTIMAL study is to demonstrate that the adjunction of Maraviroc to a combination of antiretroviral therapy in naive and late diagnosed HIV-1 infected patients counts may accelerate the kinetics of immune restoration and decrease the risk of disease progression and death.

It is a randomized, versus placebo, double-blind trial, conducted in France, Spain and Italy.

Enrollment

407 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Confirmed HIV-1 infection (ELISA and Western Blot tests positive)
CD4+ T lymphocytes below or equal 200/mm³ or previous AIDS-defining-illness at diagnosis
Patient naïve from any antiretroviral
In women, use of a contraceptive method, and lack of actual pregnancy
Patients with a coverage from social health
After informed consent

Exclusion criteria

Current pregnancy, lack of contraceptive method, breast-feeding
Current active tuberculosis (either suspected, diagnosed)
Ongoing malignancies except cutaneous Kaposi's sarcoma. Patients with a previous cancer considered as cured for at least 6 months could be included in the study
Current or previous severe cardiac failure, chronic respiratory disease, renal or liver insufficiency; any life-threatening organ failure
Cognitive impairment, psychiatric disorders, severe depressive affects, unadapted behavior
Use of cytostatic drugs, immunosuppressive agents, steroids
PMN (polymorphonuclear neutrophil) below 750/mm³, platelets below 50,000/mm³, haemoglobin below 10 g/dL; ASAT (aspartate aminotransferase), ALAT (alanine aminotransferase) or bilirubin over 2.5 ULN; lipase over 2 ULN (Upper limit of normal), serum creatinine over 1.5 ULN; proteinuria over 1g/L; INR (International Normalized Ratio) abnormal
Current or previous, during the 3 last months, use of immunomodulatory agents (G-CSF (granulocyte colony stimulating factor), IL-2 (Interleukin-2), GM-CSF (Granulocyte Macrophage colony stimulating factor), interferons, pentoxifylline)
Hypersensitivity to peanut and /or soy products